31 results about "Crohns diseases" patented technology

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintenance of a healthy gut-mucosa and / or for the provision of an increased barrier function of the gutmucosa.

A novel association between IBD and a polymorphism at amino acid residue 241 of ICAM-1 has been discovered. In accordance with the present invention there is provided methods of screening for IBD, methods for treating IBD, antibodies specifically reactive with ICAM-1 encoded by, R241 allele and kits which exploit the inventive methods.

The invention discloses a set of miRNA markers associated with Crohn disease and an application thereof. The markers are miR-219a-1-3p and / or miR-219a-5p, and the expression level of the miR-219a-1-3pand / or the miR-219a-5p in the Crohn disease is detected by adopting qRT-PCR to provide reference value for clinical diagnosis and targeted therapy of the Crohn disease. The markers are high in accuracy, sensitivity and specificity when used for the clinical diagnosis of the Crohn disease, has the advantages of convenience and quickness, and avoids the limitation of colonoscopy to some extent.

Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohns disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.

Multiple-variable dose methods for treating TNFa-related disorders, including Crohn's disease and psoriasis, comprising administering TNFa inhibitors, including TNFa antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and / or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohns disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohns disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohns disease.

The invention belongs to the field of pharmaceutical preparation and particularly relates to a cell composition and a preparation method and application thereof. The cell composition provided by the invention comprises regulatory T cells, intestinal stem cells and IL-33. The regulatory T cells and the intestinal stem cells serve as active cells, an immune system can further be regulated to inhibit excessive autoimmunity and prevent a disease from deteriorating while the intestinal inflammation of a patient is cured, and the cell composition is widely suitable for the patient with the Crohn disease. Cell factors such as the IL-33 are added into the cell composition, all components conduct the synergistic effect and jointly promote cure of the intestinal inflammation of the patient with the Crohn disease, and the therapeutic effect is remarkable.

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).

The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintainance of a healthy gut-mucosa and / or for the provision of an increased barrier function of the gut-mucosa.

Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohns Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.

The invention provides an early screening method and a kit for Crohn disease susceptibility genes, and particularly relates to a method for screening out a combination of SNP sites of Crohn disease susceptibility related genes by considering the difference between gene spectrums of sick people and healthy people. Wide (high-throughput detection sites and high-throughput detection samples) screening and inspection are carried out on genetic markers related to the Crohn disease by using a nucleic acid mass spectrometer. The method disclosed by the invention is high in detection success rate, good in technical reproducibility and high in cost performance, can realize multi-gene detection of a single small sample, and meets maximum use of the small sample; the method has the technical advantages of high accuracy and high sensitivity, the detection result is stable, and the detection positive rate is increased.

The invention discloses a Crohn disease fibrosis grading method based on multi-sequence MRI and related equipment, the method applies a trained classification network model, and the classification network model comprises a radiomics feature module and a classification module. The method comprises the following steps: controlling a radiomics feature module to obtain first radiomics features of intestinal tract fiber tissues in each abdominal cavity MRI image in a plurality of abdominal cavity MRI images of the same preset target object, and fusing the first radiomics features to obtain fused radiomics features, and controlling a classification module to determine a Crohn disease fibrosis category of the target object based on the fused radiomics features. According to the method, the abdominal cavity MRI image carrying the omnibearing characteristics of the Crohn disease fiber lesion is learned through the trained classification network model, so that the characteristic information of the Crohn disease fiber lesion can be dug in a large amount, and the Crohn disease fibrosis category of the target object can be accurately determined; and the accuracy of identifying the fibrosis category of the Crohn disease is further improved.

The present invention relates to new compounds of formula Iand pharmaceutically acceptable salts and / or co-crystals thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as medicaments for the prevention, prophylaxis of progression, and / or treatment of a disease in which modulation of extracellular (chemotactic) cytokines and / or TNF-alpha and or nuclear factor kappa B (NFKB) and / or inflammatory cells is beneficial, such as autoimmune diseases, like rheumatoid arthritis, oligoarthritis, spondyloarthropathy, psoriatic arthritis, psoriasis and inflammatory bowel diseases, such as Crohns' disease and ulcerative colitis.

The present invention relates to a method for predicting drug efficacy of infliximab for Crohn's disease and a terminal device. The method comprises: acquiring arterial phase scanning images of intestinal lesions, and extracting radiomics features from the arterial phase scanning images ; Inputting the radiomics features into the trained prediction model to obtain the drug effect prediction result, wherein the prediction model is a prediction model established by using a support vector machine classifier. By acquiring arterial phase scan images of intestinal lesions, extracting radiomics features, and then inputting the radiomics features into the trained prediction model, in order to accurately know the infliximab of Crohn's disease efficacy.

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment.Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

The invention discloses a Crohn's disease biomarker, a kit and a screening method of the biomarker. The Crohn's disease biomarker comprises microorganism homologous genes of which the KO numbers are K02761, K00368, K09953, K00285, K18692, K11895, K02796, K06148, K03710, K02240, K14393, K00689, K08652, K07251, K06286, K06175 and K15726, and a screening method of the kit. The screening method of the Crohn disease biomarker comprises the following steps: S1, acquiring microorganism sequencing data and clinical information data of a disease control group and a normal control group, and preprocessing; s2, screening the preprocessed microorganism sequencing data, and quantifying and annotating a microorganism homologous gene KO; s3, performing difference analysis on the microorganism homologous gene data of the disease patient and the healthy control group to obtain microorganism homologous genes with significant difference; s4, screening the differential homologous genes, and determining an optimal biomarker of the homologous genes; in conclusion, the Crohn disease biomarker and the screening method provided by the invention have the advantages of convenience in sampling, noninvasive property and higher clinical value.

A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).

The invention relates to the technical field of biological printing, in particular to a replaceable 3D printing nozzle for Crohn disease perianal fistula, which comprises a nozzle main body, a partition plate fixing block is arranged at the upper part in the nozzle main body, an air guide inner diameter is formed in the partition plate fixing block, a locking plate pipe diameter connecting part is arranged on one side of the air guide inner diameter, and a locking plate pipe diameter connecting part is arranged on the other side of the locking plate pipe diameter connecting part. And a clamping ball pipe diameter connecting part is arranged below the locking plate pipe diameter connecting part. According to the replaceable 3D printing nozzle for the crissum fistula of the Crohn disease, a clamping ball structure and a locking plate structure are linked through a clamping ball pipe diameter connecting part, an air guide inner diameter and a locking plate pipe diameter connecting part, so that automatic locking of the 3D printing nozzle is completed; the situation that normal use of a biological 3D printer is affected by a 3D printing nozzle gyroscope due to unstable installation in the use process of the 3D printing nozzle is avoided, after use is finished, the 3D printing nozzle can be disassembled and unlocked only by disassembling the air discharging cover and releasing air in the air guiding inner diameter, and the 3D printing nozzle is convenient to assemble and disassemble.

The present disclosure provides methods for classifying a cell as abnormal based on HD5 protein detection as well as methods for predicting prognosis of a subject with Crohn's disease based on HD5 protein detection.